Amplification of the HER-2/neu protooncogene in human endocrine tumors

B. Mark Evers, Peter L. Rády, Stephen K. Tyring, Ramon L. Sanchez, Srinivasan Rajaraman, Courtney Townsend, James C. Thompson

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Background. Amplification of HER-2/neu, a protooncogene related to the epidermal growth factor receptor, has prognostic significance in patients with breast cancer. Alterations in protooncogenes have not been determined for endocrine tumors in which prognosis is difficult to predict. We have addressed the question of whether amplification of HER-2/neu or epidermal growth factor receptor occurs in DNA from human endocrine tumor lines and have sought to characterize the HER-2/neu gene and its products in carcinoid tumors of the gut. Methods. The differential polymerase chain reaction procedure was used to detect genomic amplification in DNA samples from human endocrine tumor cell lines (BON, SIM, STAN) and from paraffin-embedded samples of carcinoid tumors. Sequencing techniques were used to determine whether mutations of the transmembrane domain of HER-2/neu existed. We then further characterized the gene products (RNA and protein) in carcinoid tumors. Results. Amplification of HER-2/neu was identified in all three endocrine tumor cell lines. HER-2/neu amplification was found in four of 10 carcinoid tumors of the gut; three of these four tumors were invasive or metastatic. In addition, HER-2/neu mRNA and protein were expressed in carcinoid tumors. Conclusions. Amplification of the HER-2/neu protooncogene occurs in endocrine tumors of the gut; quantitation of the actual copy number may be an important prognostic determinant. The unique human endocrine cell lines, established in our laboratory, will be useful models to further examine the significance of alterations of the HER-2/neu gene in endocrine tumors.

Original languageEnglish (US)
Pages (from-to)211-218
Number of pages8
JournalSurgery
Volume112
Issue number2
StatePublished - 1992

Fingerprint

Carcinoid Tumor
erbB-2 Genes
Endocrine Cells
Neoplasms
Tumor Cell Line
Epidermal Growth Factor Receptor
DNA
Paraffin
Proteins
RNA
Breast Neoplasms
Cell Line
Polymerase Chain Reaction
Messenger RNA
Mutation

ASJC Scopus subject areas

  • Surgery

Cite this

Evers, B. M., Rády, P. L., Tyring, S. K., Sanchez, R. L., Rajaraman, S., Townsend, C., & Thompson, J. C. (1992). Amplification of the HER-2/neu protooncogene in human endocrine tumors. Surgery, 112(2), 211-218.

Amplification of the HER-2/neu protooncogene in human endocrine tumors. / Evers, B. Mark; Rády, Peter L.; Tyring, Stephen K.; Sanchez, Ramon L.; Rajaraman, Srinivasan; Townsend, Courtney; Thompson, James C.

In: Surgery, Vol. 112, No. 2, 1992, p. 211-218.

Research output: Contribution to journalArticle

Evers, BM, Rády, PL, Tyring, SK, Sanchez, RL, Rajaraman, S, Townsend, C & Thompson, JC 1992, 'Amplification of the HER-2/neu protooncogene in human endocrine tumors', Surgery, vol. 112, no. 2, pp. 211-218.
Evers BM, Rády PL, Tyring SK, Sanchez RL, Rajaraman S, Townsend C et al. Amplification of the HER-2/neu protooncogene in human endocrine tumors. Surgery. 1992;112(2):211-218.
Evers, B. Mark ; Rády, Peter L. ; Tyring, Stephen K. ; Sanchez, Ramon L. ; Rajaraman, Srinivasan ; Townsend, Courtney ; Thompson, James C. / Amplification of the HER-2/neu protooncogene in human endocrine tumors. In: Surgery. 1992 ; Vol. 112, No. 2. pp. 211-218.
@article{920acada1dc1458fa1cf11aed718fdd6,
title = "Amplification of the HER-2/neu protooncogene in human endocrine tumors",
abstract = "Background. Amplification of HER-2/neu, a protooncogene related to the epidermal growth factor receptor, has prognostic significance in patients with breast cancer. Alterations in protooncogenes have not been determined for endocrine tumors in which prognosis is difficult to predict. We have addressed the question of whether amplification of HER-2/neu or epidermal growth factor receptor occurs in DNA from human endocrine tumor lines and have sought to characterize the HER-2/neu gene and its products in carcinoid tumors of the gut. Methods. The differential polymerase chain reaction procedure was used to detect genomic amplification in DNA samples from human endocrine tumor cell lines (BON, SIM, STAN) and from paraffin-embedded samples of carcinoid tumors. Sequencing techniques were used to determine whether mutations of the transmembrane domain of HER-2/neu existed. We then further characterized the gene products (RNA and protein) in carcinoid tumors. Results. Amplification of HER-2/neu was identified in all three endocrine tumor cell lines. HER-2/neu amplification was found in four of 10 carcinoid tumors of the gut; three of these four tumors were invasive or metastatic. In addition, HER-2/neu mRNA and protein were expressed in carcinoid tumors. Conclusions. Amplification of the HER-2/neu protooncogene occurs in endocrine tumors of the gut; quantitation of the actual copy number may be an important prognostic determinant. The unique human endocrine cell lines, established in our laboratory, will be useful models to further examine the significance of alterations of the HER-2/neu gene in endocrine tumors.",
author = "Evers, {B. Mark} and R{\'a}dy, {Peter L.} and Tyring, {Stephen K.} and Sanchez, {Ramon L.} and Srinivasan Rajaraman and Courtney Townsend and Thompson, {James C.}",
year = "1992",
language = "English (US)",
volume = "112",
pages = "211--218",
journal = "Surgery",
issn = "0039-6060",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Amplification of the HER-2/neu protooncogene in human endocrine tumors

AU - Evers, B. Mark

AU - Rády, Peter L.

AU - Tyring, Stephen K.

AU - Sanchez, Ramon L.

AU - Rajaraman, Srinivasan

AU - Townsend, Courtney

AU - Thompson, James C.

PY - 1992

Y1 - 1992

N2 - Background. Amplification of HER-2/neu, a protooncogene related to the epidermal growth factor receptor, has prognostic significance in patients with breast cancer. Alterations in protooncogenes have not been determined for endocrine tumors in which prognosis is difficult to predict. We have addressed the question of whether amplification of HER-2/neu or epidermal growth factor receptor occurs in DNA from human endocrine tumor lines and have sought to characterize the HER-2/neu gene and its products in carcinoid tumors of the gut. Methods. The differential polymerase chain reaction procedure was used to detect genomic amplification in DNA samples from human endocrine tumor cell lines (BON, SIM, STAN) and from paraffin-embedded samples of carcinoid tumors. Sequencing techniques were used to determine whether mutations of the transmembrane domain of HER-2/neu existed. We then further characterized the gene products (RNA and protein) in carcinoid tumors. Results. Amplification of HER-2/neu was identified in all three endocrine tumor cell lines. HER-2/neu amplification was found in four of 10 carcinoid tumors of the gut; three of these four tumors were invasive or metastatic. In addition, HER-2/neu mRNA and protein were expressed in carcinoid tumors. Conclusions. Amplification of the HER-2/neu protooncogene occurs in endocrine tumors of the gut; quantitation of the actual copy number may be an important prognostic determinant. The unique human endocrine cell lines, established in our laboratory, will be useful models to further examine the significance of alterations of the HER-2/neu gene in endocrine tumors.

AB - Background. Amplification of HER-2/neu, a protooncogene related to the epidermal growth factor receptor, has prognostic significance in patients with breast cancer. Alterations in protooncogenes have not been determined for endocrine tumors in which prognosis is difficult to predict. We have addressed the question of whether amplification of HER-2/neu or epidermal growth factor receptor occurs in DNA from human endocrine tumor lines and have sought to characterize the HER-2/neu gene and its products in carcinoid tumors of the gut. Methods. The differential polymerase chain reaction procedure was used to detect genomic amplification in DNA samples from human endocrine tumor cell lines (BON, SIM, STAN) and from paraffin-embedded samples of carcinoid tumors. Sequencing techniques were used to determine whether mutations of the transmembrane domain of HER-2/neu existed. We then further characterized the gene products (RNA and protein) in carcinoid tumors. Results. Amplification of HER-2/neu was identified in all three endocrine tumor cell lines. HER-2/neu amplification was found in four of 10 carcinoid tumors of the gut; three of these four tumors were invasive or metastatic. In addition, HER-2/neu mRNA and protein were expressed in carcinoid tumors. Conclusions. Amplification of the HER-2/neu protooncogene occurs in endocrine tumors of the gut; quantitation of the actual copy number may be an important prognostic determinant. The unique human endocrine cell lines, established in our laboratory, will be useful models to further examine the significance of alterations of the HER-2/neu gene in endocrine tumors.

UR - http://www.scopus.com/inward/record.url?scp=0026770232&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026770232&partnerID=8YFLogxK

M3 - Article

C2 - 1353638

AN - SCOPUS:0026770232

VL - 112

SP - 211

EP - 218

JO - Surgery

JF - Surgery

SN - 0039-6060

IS - 2

ER -